Well Researched

Thymosin Alpha 1

Synthetic Thymic Hormone | Immune System Modulation

Thymosin Alpha 1 (Ta1/Thymalfasin/Zadaxin) is a synthetic 28-amino acid peptide identical to the naturally occurring thymic hormone. With over 11,000 patients studied across 30+ clinical trials, it holds FDA orphan drug designations for four conditions and is approved in 35+ countries worldwide. Ta1 demonstrates exceptional safety with less than 1% serious adverse events while providing comprehensive immune system modulation.

Daily dose

1.6mg

Frequency

2x weekly

Cycle length

6 months

Storage

2-6°C

Key benefits

Comprehensive immune system modulation with exceptional safety profile. FDA orphan drug designations for multiple conditions. Approved in 35+ countries with extensive clinical validation.

How it works

Ta1 activates immune responses through multiple TLR pathways, enhances T-cell maturation, stimulates NK cells, and modulates cytokine production. Provides balanced immune enhancement without excessive inflammation.

Dosage protocols

Goal

Standard immune support

Dose

1.6mg · 2x weekly

Route

SubQ

Goal

Acute conditions

Dose

1.6mg · Daily or 2x daily

Route

SubQ or IM

Goal

Cancer/hepatitis support

Dose

1.6mg · 2x weekly

Route

SubQ

Goal

Nasal administration

Dose

500-1000mcg · 1-2x daily

Route

Intranasal

Research indications

immunity

Primary Immunodeficiencies — FDA orphan drug designation for DiGeorge syndrome with documented restoration of T-cell function and immune competence.

Vaccine Response Enhancement — Enhances immunogenicity in elderly and immunocompromised patients with improved antibody responses.

HIV/AIDS Immune Support — Restores CD4+ T-cell counts and reduces opportunistic infections with sustained immunological improvement.

inflammation

Cytokine Storm Mitigation — Reduces pro-inflammatory cytokines by 40-60% while maintaining balanced immune responses.

Chronic Inflammatory Conditions — Modulates inflammatory responses in hepatitis, pancreatitis, and autoimmune conditions.

recovery

Post-Surgical Immune Recovery — Accelerates immune system recovery following major surgery or chemotherapy through lymphocyte restoration.

Exercise-Induced Immunosuppression — Counters stress-induced immune suppression in athletes and high-stress situations.

anti Aging

Thymic Regeneration — Supports age-related thymic decline through hormone replacement therapy in elderly populations.

Immune Senescence Prevention — Delays age-related immune deterioration with improved vaccine responses.

cellular

Antioxidant Enzyme Enhancement — Increases antioxidant enzyme activity providing cellular protection against oxidative damage.

Mitochondrial Function Support — Supports cellular energy metabolism and protects against age-related mitochondrial decline.

Administration

injectable

nasal

Interactions

Contraindicated

Immunosuppressive Agents — Absolute contraindication in organ transplant recipients. Fatal immune hemolytic anemia and graft rejection documented in hematopoietic stem cell transplant patients.

Monitor Combination

Corticosteroids — Pharmacodynamic antagonism as Ta1 blocks steroid-induced thymocyte apoptosis, potentially reducing immunosuppressive effects.

Synergistic

Interferon-α — Enhanced antiviral efficacy in hepatitis treatment with synergistic NK cell activation. Monitor for increased fever, fatigue, and neutropenia.

Compatible

Vaccines — Intended therapeutic effect enhancing vaccine immunogenicity, particularly beneficial in elderly and immunocompromised patients.

Compatible

Chemotherapy Agents — Protective effects against cytotoxic bone marrow damage while maintaining standard oncology monitoring protocols.

Safety notes

Exceptional safety profile (<1% serious adverse events)

Contraindicated in organ transplant recipients

Monitor for injection site reactions

Not recommended during pregnancy

Consult physician for proper medical supervision

Research studies

Comprehensive Safety Evaluation Study (2024)

Multiple species | Up to 16mg/kg | 6-12 months | Exceptional safety profile

Comprehensive review across 11,000+ patients in 30+ clinical trials showing <1% serious adverse events, establishing excellent long-term safety profile for potential clinical applications.

View study →

Post-Acute COVID-19 Immune Restoration Study

Human | 1.6mg SC twice weekly | 12 weeks | Immune homeostasis restoration

Study demonstrating Ta1's ability to restore immune homeostasis in lymphocytes during post-acute sequelae of SARS-CoV-2 infection with normalized T-cell populations and reduced inflammatory markers.

View study →

Cytokine Storm Mitigation in COVID-19 Patients

Human | 1.6mg SC daily | 7 days | 40-60% cytokine reduction

Clinical study showing significant reduction in pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 while maintaining balanced immune responses in coronavirus disease patients.

View study →

COVID-19 Treatment Efficacy Study (2020)

Human | 1.6mg SC twice daily | 14 days | 30% vs 11% mortality reduction

Randomized trial demonstrating significant mortality reduction in severe COVID-19 patients through restoration of lymphocytopenia and reversal of exhausted T cells. Primary endpoint showed dramatic improvement in survival rates.

View study →

TESTS Phase 3 Sepsis Trial (NCT02867267)

Human | 1.6mg SC twice daily | 28 days | Mixed mortality outcomes

Largest randomized controlled trial with 1,106 sepsis patients evaluating mortality benefit. While overall results were negative, subgroup analysis suggested potential benefits in specific populations.

View study →

Thymalfasin COVID-19 Pilot Trial (NCT04487444)

Human | 1.6mg SC daily | 5 days | Improved lymphocyte recovery

Pilot study in 49 hospitalized COVID-19 patients with hypoxemia and lymphocytopenia showing enhanced immune recovery but mixed clinical outcomes. Completed recruitment with published safety data.

View study →

Related compounds

Thymulin LL-37 KPV Glutathione